Affymetrix

Affymetrix is a company that specializes in developing and providing advanced technologies for the analysis of biological systems at the gene, protein, and cell levels. Its products are designed to facilitate genetic analysis within the life sciences and clinical healthcare markets. Affymetrix offers a range of life science tools and diagnostic products, including gene expression and genotyping services, which support both clinical diagnostics and research applications. By enabling comprehensive analysis of biological data, Affymetrix plays a significant role in advancing the understanding of molecular biology and improving healthcare outcomes.

Sue Siegel

President and Board Member

5 past transactions

eBioscience

Acquisition in 2011
eBioscience is a prominent provider of reagents essential for immunology and oncology research, specializing in flow cytometry. The company offers a vast array of antibodies, ELISAs, and proteins that support life science research and diagnostics. Recognized as an industry leader, eBioscience is particularly noted for its extensive selection of multicolor flow cytometry reagents, producing over 800 new products annually. Their innovative portfolio encompasses antibodies, fluorochromes, and other reagents tailored for applications in immunology, oncology, cell biology, stem cell biology, and diagnostics. As a privately held entity, eBioscience continues to play a critical role in advancing research capabilities within the pharmaceutical sector.

Panomics

Acquisition in 2008
Panomics, founded in 2000 by Yuling Luo and Jason Li and based in California, specializes in providing a suite of assay products for low to mid-plex genetic, protein, and cellular analysis applications. The company is dedicated to delivering solutions for Parallel Quantitative Biology, which involves a contextual and systems-level measurement of genes, proteins, and their cellular functions. Through its innovative products, Panomics aims to support clients in their research and development efforts across various scientific fields.

ParAllele Bioscience

Acquisition in 2005
Angel Dough Ventures is a startup accelerator that identifies new business ideas as well as develops and launches new products and services into the market. It also reviews customer feedback and analyzes metrics to transform and improve its businesses. Angel Dough Ventures was founded by Andrew Hazen and is headquartered in Hicksville, New York.

Neomorphic

Acquisition in 2000
Neomorphic, based in Berkeley, California, specializes in computational genomics. It employs proprietary software algorithms and computing infrastructure to analyze, assemble, and annotate genomic and expressed gene sequence data. The company's bioinformatics capabilities have been validated in various scientific projects, including the Drosophila annotation jamboree and the Genome Annotation Assessment Project, demonstrating its superior accuracy in identifying genes and regulatory regions within genomic sequences. Neomorphic's clients comprise prominent pharmaceutical and genomics companies such as Celera Genomics, Millennium Pharmaceuticals, and Monsanto.

Genetic MicroSystems

Acquisition in 1999
Genetic Microsystems is a privately held instrumentation company that specializes in DNA array technology. The company provides advanced genomics research and drug discovery by providing high-performance systems that enable scientists to use micro-array technology in their own labs and in experiments of their own design.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.